towards improved death receptor targeted therapy for ... - TI Pharma

Chapter 3
Reference List
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277‐
300.
2. Blackstock AW, Govindan R. Definitive chemoradiation
for the treatment of locally
advanced non small‐cell lung cancer. J Clin Oncol 2007; 25(26):4146‐4152.
3. Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK et al. Chemoradiotherapy with or
without AE‐941 in stage III non‐small cell lung cancer: a randomized phase III trial. J Natl
Cancer Inst 2010; 102(12):859‐865.
4. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between
life and death. Int J Biochem Cell Biol 2007; 39(7‐8):1462‐1475.
5. Gonzalvez F, Ashkenazi A. New insights
into apoptosis signaling by Apo2L/TRAIL. Oncogene
2010; 29(34):4752‐4765.
6. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset,
progression and therapy. Nat Rev Cancer 2008; 8(10):782‐798.
7. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF et al.
Oncogenic K‐Ras turns death receptors into metastasis‐promoting receptors in human and
mouse colorectal cancer cells. Gastroenterology 2010; 138(7):2357‐2367.
8. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in
apoptosis‐resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006;
290(1):G129‐G136.
9. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J et al. Kinome
profiling of non‐canonical TRAIL signaling reveals RIP1‐Src‐STAT3 dependent invasion in
resistant non‐small cell
lung cancer cells. J Cell Sci 2012.
10.
Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF‐kappaB
pathway enhances TRAIL‐mediated apoptosis in neuroblastoma cells. Cancer Gene Ther
2004; 11(10):681‐690.
11. Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL‐mediated apoptosis requires
NF‐kappaB inhibition and the mitochondrial permeability transition in human hepatoma
cells. Hepatology 2002; 36(6):1498‐1508.
12. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D et al. TRAIL promotes the
survival and proliferation of primary human vascular endothelial cells by activating the Akt
and ERK pathways. Circulation 2003; 107(17):2250‐2256.
13. Thiefes A, Wolter S, Mushinski JF, Hoffmann E, ttrich‐Breiholz O, Graue N et al.
Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase‐inactive mutant of
the protein kinase TAK1 sensitizes cells to apoptosis and
affects a distinct spectrum of
tumor necrosis factor [corrected] target genes. J Biol Chem 2005; 280(30):27728‐27741.
14. Vaculova A, Hofmanova J, Soucek K, Kozubik A. Different modulation of TRAIL‐induced
apoptosis by inhibition of pro‐survival pathways in TRAIL‐sensitive and TRAIL‐resistant
colon cancer cells. FEBS Lett 2006; 580(28‐29):6565‐6569.
15. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE et al. Sensitization of
apoptotically‐resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38
mitogen‐activated protein kinase signaling. Int J Oncol 2004;
24(6):1473‐1480.
16. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P. Activation of ERK1/2 protects
melanoma cells from TRAIL‐induced apoptosis by inhibiting Smac/DIABLO release from
mitochondria. Oncogene 2003; 22(19):2869‐2881.
17. Mathews ST, Plaisance EP, Kim T. Imaging systems for westerns: chemiluminescence vs.
infrared detection. Methods Mol Biol 2009; 536:499‐513.
18. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus‐
mediated RNA interference. Cancer Cell 2002; 2(3):243‐247.
19. van Leuken R, Clijsters L, van ZW, Lim D, Yao X, Wolthuis
RM et al. Polo‐like kinase‐1
controls Aurora A destruction by activating APC/C‐Cdh1. PLoS One 2009; 4(4):e5282.
‐ 56 ‐